Biovail, Par Pharmaceutical, Purdue Pharma, J&J neurology news

The U.S. District Court for the District of Delaware ruled that Purdue's U.S. Patents Nos. 6,254,887 and 7,074,430 covering Ultram ER tramadol extended-release tablets were invalid due to obviousness. The court also found that Par infringed the patents through its submission of an ANDA for generic tramadol ER. ...